February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
November 2009 in “Eclética Química” The conclusion cannot be provided as the document content is not available.
11 citations
,
May 1990 in “Journal of Dermatological Science” Diazoxide applied to the skin can increase hair growth without harmful side effects.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
May 2024 in “Australasian journal of dermatology” Bicalutamide is more effective and safer than spironolactone for treating female hair loss.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
38 citations
,
May 1982 in “PubMed” Intralesional steroid injections can effectively treat calcinosis and ulcers in scleroderma.
Baricitinib is more effective than methotrexate for severe alopecia areata.
June 2021 in “Clinical neuropsychopharmacology and therapeutics” Valproic acid can cause hair color change in older men.
128 citations
,
January 2001 in “American Journal of Clinical Dermatology” Coal tar shampoos, salicylic acid, and topical corticosteroids are effective for scalp psoriasis, with Vitamin D3 analogues also showing benefits; severe cases may require stronger medication with more risks.
1 citations
,
April 2007 in “PubMed” Tacrolimus helps mice grow hair by activating hair follicles.
March 2023 in “The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy” Both new minoxidil formulations effectively stimulated hair growth.
5 citations
,
January 2009 Betamethasone is more effective than Tacrolimus and soft paraffin for hair regrowth in patchy alopecia areata.
14 citations
,
July 2017 in “Fitoterapia” Oleanolic acid promotes hair growth by increasing cell proliferation through the Wnt/β-catenin pathway.
1 citations
,
February 2025 in “Toxicology in Vitro” Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
9 citations
,
November 1980 in “Geburtshilfe und Frauenheilkunde” Fenoterol treatment causes increased hair growth due to higher metabolism in hair follicles, not hormones.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
January 1988 in “Chemical and Pharmaceutical Bulletin” IND-Ca ointment effectively reduces inflammation with minimal skin irritation.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.
The TrichoConcept™ line is effective for personalized hair loss treatments.
Scalp med(R) effectively and safely improves hair count and thickness in men with androgenetic alopecia.
August 2025 in “Saudi Pharmaceutical Journal” The ointment effectively treats neurodermatitis and chronic eczema without causing skin irritation.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
3 citations
,
November 2021 in “World Journal of Clinical Pediatrics” Vitamin D might help treat some types of hair loss, but more research is needed.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
January 2024 in “Aesthetic Plastic Surgery” Botox can help prevent hair loss by blocking cell death in scalp cells.
50 citations
,
June 1999 in “Annals of Oncology” Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.